Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) FCF Margin (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed FCF Margin for 10 consecutive years, with 452.8% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, FCF Margin changed N/A year-over-year to 452.8%, compared with a TTM value of 1725.6% through Sep 2025, changed N/A, and an annual FY2024 reading of 1935.6%, changed N/A over the prior year.
  • FCF Margin was 452.8% for Q4 2024 at Lisata Therapeutics, down from 210266.67% in the prior quarter.
  • Across five years, FCF Margin topped out at 452.8% in Q4 2024 and bottomed at 452.8% in Q4 2024.